Adlyxin (lixisenatide) / Zealand Pharma, Royalty, Sanofi  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adlyxin (lixisenatide) / Sanofi
2014-002178-35: The renal effects of lixisenatide (a novel, gut-hormone based diabetes drug) and insulin glulisine (a common, wideley diabetes drug) Een onderzoek naar de werking van lixisenatide (een nieuw, op darmhormoon gebaseerd diabetes medicijn) en insuline glulisine (een veelgebruikt gangbaar diabetes medicijn) op de nierfunctie

Ongoing
4
40
Europe
Lixisenatide, Insulin glulisine, Lyxumia, Apidra, Lyxumia, Apidra
VU University Medical Center, VU University Medical Center, Sanofi-Aventis Netherlands B.V.
Type 2 Diabetes Mellitus Type 2 Diabetes
 
 
2016-001758-17: Lixisenatide Arterial Stiffness Trial

Ongoing
4
120
Europe
Lixisenatide (Lyxumia), Suspension for injection in pre-filled pen, Lyxumia
King's College London, Guy's and St Thomas' NHS Foundation Trust, Sanofi Aventis Limited
Type 2 diabetes, Diabetes, Diseases [C] - Hormonal diseases [C19]
 
 
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes

Not yet recruiting
4
600
 
DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin)
Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project
Type 2 diabetes
 
 
NCT05804513: The Effect of Lixisenatide on the Effect of Pituitary Hormones

Recruiting
4
10
Europe
Placebo, Sodium chloride 0.9% solution, Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector, Lyxumia
University of Tartu, Tartu University Hospital
Healthy, Type 1 Diabetes
10/23
12/23

Download Options